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Abstract. Obesity is a growing worldwide medical problem,
as it pre-disposes the affected hosts to a number of severe
diseases, including postmenopausal breast cancer. Obesity
development is characterised, amongst others, by aberrant
secretion of adipokines. White fat tissue infiltrating macro-
phages secrete tumour necrosis factor-· (TNF-·) so that its
circulating levels correlate positively with body mass index
(BMI). In the study presented here, the effect of TNF-· on cell
proliferation, cell signalling pathway activation and cell cycle
in two breast cancer cell lines and one breast epithelial cell
lines was assessed to determine the contribution of TNF-· on
breast cancer progression and aetiology, respectively. TNF-·
acted differently on all three cell lines. In MDA-MB-231
breast cancer cells, cell proliferation and PI3-kinase activation
were not affected, while MAP-kinase activation and cell cycle
progression were decreased, with indications of increased
apoptosis. This suggests a growth inhibitory function of
TNF-· in these cells. In SK-BR-3 breast cancer cells, cell
proliferation and cell signalling pathway activation increased,
while cell cycle progression decreased, which contradictorily
suggests both growth promoting and growth inhibiting
properties of TNF-· on these cells. This makes TNF-· an
unlikely candidate for a general contribution to the link
between obesity and breast cancer progression, however,
individual tumours may be responsive to a proliferative
signal of TNF-·. In MCF-10A breast epithelial cells, cell
proliferation and MAP-kinase activation increased, while cell
cycle progression was unaffected. This suggests a strong
proliferative response in these cells, suggesting the possibility
that TNF-· may contribute to breast cancer aetiology as a
novel link between obesity and increased risk of breast cancer
development.
Introduction
Obesity is a risk factor for the development of post-
menopausal breast cancer (1-3). Despite numerous studies,
the molecular mechanism by which obesity may contribute to
breast cancer aetiology and progression is still poorly under-
stood, suggesting a complex multi-mechanism of interaction.
Obesity is characterised, amongst others, by a change in
adipocyte secreted adipokines (4-6). Plasma concentrations
of several well-known adipokines are positively correlated
with BMI, such as leptin (7), interleukin-6 (IL-6) (8) and
tumour necrosis factor-· (TNF-·) (9). In the study presented
here, the contribution of TNF-· in the link between obesity
and progression or aetiology of breast cancer is assessed.
TNF-· is a cytokine involved in the induction of
inflammation and initiation of an acute phase immune
response. When cells are stimulated to secrete TNF-·,
membrane-bound precursor molecules on the surface of
secreting cells are cleaved to form 51 kDa circulating TNF-·,
consisting of three 17 kDa TNF-· molecules (10). Its name
derived from the initial observation that this cytokine was
able to induce cell death in the murine fibrosarcoma L-929
cell line (11). Endocrine signalling is accomplished by
circulating TNF-· binding to and activating its specific
receptor TNF-receptor 1 (TNF-R1) on target cells. The
receptor is expressed ubiquitously in all human tissues,
including breast epithelial cells (12). Thus TNF-· signalling
in breast epithelial cells and breast cancer cells could be
affected by obesity associated increases in TNF-· circulatory
concentration.
Previous in vitro studies observed conflicting results as
to the effect of TNF-· on growth promotion in breast cancer
cells. It was found that 20 ng/ml TNF-· increased cell
proliferation in T47D human breast cancer cells and induced
significant activation of PI3-kinase pathway, MAP-kinase
pathway and JAK/STAT pathway (13), suggesting a growth
promoting effect of TNF-· on these cells. Conversely, treat-
ment with 10 ng/ml TNF-· for 24 h increased G1-phase
population, while reducing the cell population in S-phase
and G2-phase (14), suggesting a cell cycle inhibiting effect
on these cells. Thus TNF-· had different, indeed opposing
effects on T47D breast cancer cells. In MCF-7 breast cancer
cells 10 ng/ml TNF-· decreased cell proliferation (15) and
an increase in G1-phase cell population was observed after
treatment with 10 ng/ml TNF-· for 36 h in MCF-7 cells (16),
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suggesting a growth inhibiting effect in this cell line. In
different MCF-7 cell subtypes, however, opposing effects of
TNF-· on cell proliferation were observed (17). Thus, the
effect of TNF-· on breast cancer cell growth is not elucidated
satisfactorily, while the effect of TNF-· on human breast
epithelial cells has not been investigated at all.
The study presented here aimed to assess the effect of
TNF-· on cell proliferation, PI3-kinase and MAP-kinase
cell signalling pathway activation and on changes in the
distribution of the cell population across cell cycle stages in
an in vitro cell culture model. It was of particular interest to
determine the possible different impact of TNF-· on breast
cancer cells compared to normal breast epithelial cells as a
novel way of assessing the molecular mechanisms involved
in the link between obesity and breast cancer progression
and aetiology. In order to assess the contribution of TNF-·
on breast cancer progression, two breast cancer cell lines
were selected, MDA-MB-231 and SK-BR-3 breast cancer
cells. The contribution of TNF-· on breast cancer aetiology
was assessed using normal MCF-10A breast epithelial cells.
Previous experiments were performed in oestrogen receptor
(ER) positive cells. In the study presented here, ER negative
cell lines were used.
Materials and methods
Materials. Human Caucasian breast adenocarcinoma cells
MDA-MB-231 (Cat No. 92020424, passage No. 36) were
purchased from the European Collection of Cell Cultures
(ECACC, Salisbury, UK). Human Caucasian breast adeno-
carcinoma cells SK-BR-3 (ATCC No. HTB-30, passage
No. 28) were purchased from the American Type Culture
Collection (ATCC, Manassas, USA). MDA-MB 231 cells
and SK-BR-3 cells were routinely cultured in RPMI-1640
Medium (including 25 mM HEPES, 1x Glutamax) [Gibco
(Invitrogen), Paisley, UK, Cat No. 72400] supplemented
with 10% FCS (Pierce Biosciences, Cramlington, UK, Cat
No. CHD0413) and 100 U/ml penicillin and 100 μg/ml
streptomycin (Gibco, Cat No. 15140). MDA-MB-231 breast
cancer cells have mutations in genes coding for RAS and
RAF, increasing their kinase activity, while SK-BR-3 breast
cancer cells possess wild-type genes coding for RAS and
RAF (18). RAS and RAF are kinase members of the MAP-
kinase cell signalling pathway. Human Caucasian breast
epithelial cells MCF-10A (ATCC No. CRL-10317, passage
No. 102) were purchased from ATCC and were cultured in
DMEM/F-12 Medium (BioWhittaker, UK [Lonza Biologics],
Slough, UK, Cat No. BE12-7199) supplemented with 5%
Horse Serum (Sigma-Aldrich, Gillingham, UK, Cat No.
H1138), 10 μg/ml human insulin (Sigma, Cat No. I9278),
0.5 μg/ml hydrocortisone (Sigma, Cat No. H0888), 20 μg/ml
human epidermal growth factor (Invitrogen, Cat No. 13247-
051), 100 ng/ml cholera toxin (Sigma, Cat No. 8052), 50 U/ml
penicillin and 50 μg/ml streptomycin (Gibco). Starvation
medium was RPMI-1640 (25 mM HEPES, 1x Glutamax)
(Gibco) supplemented with 100 U/ml penicillin and 100 μg/ml
streptomycin (Gibco) for MDA-MB 231 cells and SK-BR-3
cells and DMEM/F12 (BioWhittaker) supplemented with
100 U/ml penicillin and 100 μg/ml streptomycin for MCF-
10A cells. Human recombinant TNF-· was purchased from
Sigma (Cat No. T0157). Cell culture conditions were 37˚C in
humidified air supplemented to contain 5% CO2.
BrdU-incorporation assay. Cell proliferation was detected
using a colorimetric Cell Proliferation ELISA Kit (Roche
Diagnostics, Penzberg, Germany, Cat No. 11 647 229 001),
which assesses DNA replication by measuring bromode-
oxyuridine (BrdU) incorporation. Cells (5x103 cells/well)
from each cell line were plated in 96-well plates (Fisher
Scientific, Cat No. 167008) with 100 μl/well growth medium
and incubated for 24 h at 37˚C. Cells were washed once in
100 μl/well sterile PBS and incubated in starvation medium
for 24 h. After starvation, cells were washed as before and
treated for 24 or 48 h with 10 ng/ml TNF-· in 100 μl/well
starvation medium. During treatment, medium was supple-
mented with 10 μM BrdU. Incorporated BrdU was detected
according to the manufacturer's instructions. In brief, cells
were fixed and incubated with supplied peroxidase conjugated
anti-BrdU antibody. Bound antibody was detected by colori-
metric turn-over. Colour development was quantified on
μQuant microplate spectrophotometer (BioTek, UK) by
measuring absorption at 450 nm with a reference wave-
length of 690 nm. Three experiments were performed for
each cell line and each time point. Each experiment consisted
of six replicates for each treatment, i.e. six wells for control
and six wells for treatment.
Phospho-kinase ELISA. Cell-based ELISA phospho-AKT
(S473) immunoassay (Cat No. KCB887) and phospho-
ERK1/ERK2 (T202/Y204) immunoassay (Cat No.
KCB1018) were purchased from R&D Systems (Abingdon,
UK). Cells from all three cell lines were plated into a supplied
clear bottom black 96-well plate at a density of 5x103 cells/
well with 100 μl/well growth medium and incubated for 24 h
at 37˚C. Cells were washed once in 100 μl/well sterile PBS
and incubated in starvation medium for 24 h. After starvation,
cells were washed as before and treated with 10 ng/ml
TNF-· in 100 μl/well starvation medium for times indicated
in Fig. 2. Phosphorylation of AKT and ERK1/2 was then
assessed following the manufacturer's instructions. In brief,
after fixing, the cells were incubated with anti-phospho-AKT
or anti-phospho-ERK1/2 specific antibody in conjunction
with anti-total AKT or anti-total ERK1/2 specific antibody,
respectively. Phospho-specific antibodies were of mouse
origin, while antibodies for the total protein were produced in
rabbits. Each antibody was identified by mouse or rabbit
specific secondary antibodies, which were tagged with HRP
or AP, respectively, allowing for simultaneous quantification
of phosphorylated and total AKT or ERK1/2 protein. After
antibody incubation, excess secondary antibody was removed
by several washes in supplied wash buffer and PBS, before
two supplied fluorescent substrates were added. Fluorescence
was measured on Fluoroskan Ascent microplate reader
(Labsystem, UK) with excitation at 544 nm and emission at
590 nm (phosphorylated protein), followed by a second
read with excitation at 355 nm and emission at 460 nm (total
protein). For each cell line two experiments were performed
to assess AKT-phosphorylation and two to assess ERK1/2-
phosphorylation after TNF-· treatment. Each experiment
included two replicates for each treatment time and the control.
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Flow cytometry. Changes in the cell distribution across cell
cycle stages were assessed by measurement of DNA-content
in cells. The DNA specific dye was propidium iodide (PI)
(Sigma, Cat No. P4170). Cells were plated at 5x105 cells/
well in 6-well plates with 3 ml growth medium and incubated
for 24 h at 37˚C. Cells were starved for 24 h and then treated
with 10 ng/ml TNF-· for 24 h. Cells were harvested by
trypsin, centrifuged at 500 x g for 5 min and each sample
was resuspended in 100 μl PBS and 900 μl 70% (v/v) ice-
cold ethanol before being incubated at 4˚C for 30 min.
Samples were centrifuged at 10,000 x g for 5 min, resuspended
in 1 ml PBS and again centrifuged at 10,000 x g for 5 min.
Pellet was resuspended in 500 μl extraction buffer (4 mM
citric acid, 0.2 M Na2HPO4, pH 7.8) and 500 μl PBS and
incubated at room temperature for 5 min. Cells were centri-
fuged at 10,000 x g for 5 min and the pellet was resuspended
in 500 μl DNA staining solution (20 μg/ml propidium
iodide and 0.2 mg/ml DNase free RNase). The cells were
incubated at room temperature for 30 min. Flow cytometry
of PI stained cells was performed using a Coulter Epics
XLMCL flow cytometer (Beckman Coulter, UK). Data
were captured and analysed using EXPO 32 Software
(Applied Cytometry Systems, Sheffield, UK). Cell cycle
distribution was assessed from linear FL-2 area vs. width
plots. The percentage of cells in the three cell cycle
phases (G1, S and G2) was calculated from histograms of
linear FL-2 area plots after assessing 10,000 events.
Additionally, percentage of cells with a DNA content <2N
(sub-G1) was measured as an indication of apoptosis. Three
experiments were performed for each cell line, containing
two replicates for control and treatment.
Statistical analysis. Cell proliferation results were assessed
using one-way ANOVA. Cell signalling pathway activation
and cell cycle results were assessed using Dunnett's post-hoc
t-test following univariate analysis of variance. Changes
were defined as significantly different at p<0.05.
Results
Cell proliferation. Cell proliferation of all cell lines was
assessed after 10 ng/ml TNF-· treatment for 24 or 48 h (Fig. 1).
Untreated control cells were incubated in starvation medium
(Control) at all times. All results are presented as percentage
change from this control. In MDA-MB-231 breast cancer
cells, cell proliferation did not significantly change after 24-
or 48-h treatment with 10 ng/ml TNF-·. In SK-BR-3 breast
cancer cells, cell proliferation increased significantly by 31%
after 24-h treatment (p=0.016) and by 59% after 48-h treat-
ment (p<0.001) with 10 ng/ml TNF-·. In MCF-10A normal
breast epithelial cells, cell proliferation increased signi-
ficantly by 26% after 24-h treatment (p<0.001) and by 38%
after 48-h treatment (p=0.002) with 10 ng/ml TNF-·.
Cell signalling pathway activation. Phosphorylation of AKT
or ERK1/2 was measured after treatment with 10 ng/ml
TNF-· for between 5-20 min (Fig. 2). Untreated control cells
were incubated in starvation medium (Control) at all times.
All results are presented as percentage change of this control.
In MDA-MB-231 breast cancer cells, AKT-phosphorylation
did not change significantly after treatment between 5
and 20 min with 10 ng/ml TNF-·. ERK1/2-phosphorylation
was significantly decreased by 22% after 5-min treatment
(p=0.044) with 10 ng/ml TNF-· (Fig. 2A). In SK-BR-3 breast
cancer cells, AKT-phosphorylation increased significantly
by 66, 72 and 91% after 5-min (p=0.04), 10-min (p=0.025)
and 20-min treatment (p=0.006) with 10 ng/ml TNF-·,
respectively compared to untreated control. ERK1/2-
phosphorylation increased significantly by 47% after 5-min
treatment (p=0.027) with 10 ng/ml TNF-· (Fig. 2B). In
MCF-10A normal breast epithelial cells, AKT-phospho-
rylation did not change significantly. A non-significant
increase of 77% (p=0.169) after 20 min of treatment with
10 ng/ml TNF-· compared to untreated control was,
however, observed. ERK1/2-phosphorylation increased
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Figure 1. Changes in cell proliferation after treatment with 10 ng/ml TNF-· (A) 24 h or (B) 48 h in MDA-MB-231 breast cancer cells, SK-BR-3 breast cancer
cells and MCF-10 breast epithelial cells. Bars represent BrdU-incorporation in relation to the respective control and are expressed as a percentage thereof.
Error bars represent ± SEM of three experiments, each consisting of six replicates, i.e. 18 data points for each bar. *Significance value compared to
control, obtained using one-way ANOVA analysis. (*0.05>p>0.01; **0.01>p>0.001; ***p<0.001).
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significantly by 144, 103 and 108% after 10-min (p=0.003),
15-min (p=0.025) and 20-min treatment (p=0.019) with
10 ng/ml TNF-· compared to untreated control (Fig. 2C).
Cell cycle. Cell cycle profiles for all cell lines were established
after treatment with 10 ng/ml TNF-· for 24 h (Table I).
In MDA-MB-231 breast cancer cells, population of the G1-
phase decreased significantly by 3.5 percentage points (a 6%
decrease) after 24-h treatment (p=0.006) with 10 ng/ml TNF-·
compared to G1-phase population of control cells. S-phase
population decreased significantly by 1.8 percentage points
(a 15% decrease) after 24-h treatment (p<0.001) with 10 ng/ml
TNF-· compared to S-phase population of control cells. No
significant difference in G2-phase population after 24-h
treatment (p=0.233) with 10 ng/ml TNF-· compared to G2-
phase population of control cells was observed. Additionally,
the sub-G1 population increased significantly by 4.66
percentage points (a 27% increase) after treatment with
10 ng/ml TNF-· for 24 h (p<0.001). In SK-BR-3 breast
cancer cells G1-phase population was not significantly
different between 24-h treatment (p=0.811) with 10 ng/ml
TNF-· and the control. Population of the S-phase decreased
significantly by 1.5 percentage points (a 25% decrease) after
24-h treatment (p=0.011) with 10 ng/ml TNF-· compared to
S-phase population of control cells. Population of the G2-
phase decreased significantly by 3.8 percentage points (a
24% decrease) after 24-h treatment (p=0.011) with 10 ng/ml
TNF-· compared to G2-phase population of control cells. In
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Figure 2. Changes in cell signalling pathway activation [PI3-kinase (left) and MAP-kinase (right))] with 10 ng/ml TNF-· treatment in (A) MDA-MB-231
breast cancer cells (B) SK-BR-3 breast cancer cells and (C) MCF-10A breast epithelial cells. Bars represent AKT-phosphorylation or ERK1/2-phos-
phorylation in relation to the respective control within each graph and are expressed as a percentage thereof. Error bars represent ± SEM of two
experiments, each consisting of two replicates, i.e. four data points for each bar. *Significance value compared to control, obtained using Dunnett's
post-hoc t-test following univariate analysis of variance. (*0.05>p>0.01; **0.01>p>0.001).
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MCF-10A normal breast epithelial cells no significant
difference in any cell cycle phase was observed after 24-h
treatment with 10 ng/ml TNF-· compared to control. In the
G1-phase population a non-significant decrease of 6.6
percentage points (a 12% decrease) after 24-h treatment
(p=0.051) with 10 ng/ml TNF-· compared to G1-phase
population of control cells was observed.
Discussion
Adipokines have been hypothesised as molecular explanation
of the link between obesity and increased risk of developing
postmenopausal breast cancer (19-21). Both leptin (22-26)
and adiponectin (22,27-29) have been studied in in vitro
systems and results have indicated that there is some
involvement, even though their effect on breast cancer is
diametrically opposed. Their effect on growth promotion in
breast cancer cells, however, is small and suggests that
additional factors may play a role. The fact that many more
adipokines have been discovered recently, the expression of
which being affected by obesity, makes the contribution of
other adipokines in the molecular link between obesity and
postmenopausal breast cancer likely. The effects of TNF-·
on a breast cancer cell model were therefore studied to
evaluate the contribution of TNF-· in the link between
obesity and breast cancer progression. Additionally, a normal
breast epithelial cell line was used to examine the potential
impact of TNF-· on breast cancer aetiology. The impact of
TNF-· on breast epithelial cells has not been assessed
previously and represents a novel way of assessing the impact
of adipokines on breast cancer aetiology.
In MDA-MB-231 breast cancer cells, cell proliferation
did not change after 24- or 48-h treatment with 10 ng/ml
TNF-·. Similarly, Mueller and his colleagues observed that
0.25 nM (12.75 ng/ml) TNF-· treatment alone did not change
cell proliferation in these cells (30). Thus, there is no indication
that TNF-· increases cell proliferation in these cells. In SK-
BR-3 breast cancer cells, 10 ng/ml TNF-· treatment increased
cell proliferation after 24 and 48 h of treatment. The highest
increased was observed after 48-h treatment. Similarly, Rivas
and colleagues observed an increase in SK-BR-3 cell
proliferation following 20 ng/ml TNF-· treatment for 48 h
(31). There is, therefore, good evidence that TNF-· has a
proliferative effect on SK-BR-3 breast cancer cells. Hence,
cell proliferation of the two breast cancer cell lines reacted
differently to treatment with TNF-·. While both cell lines are
ER-negative, there is a difference in HER2 expression with
SK-BR-3 cells expressing high levels and MDA-MB-231
cell expressing low levels (32). In addition, MDA-MB-231
cells carry mutations in the genes coding for kinases RAS
and RAF, that form part of the MAP-kinase cell signalling
pathway (18). These differences may contribute to the different
effect of TNF-· on these cells, which may also apply to the
other differences observed. In MCF-10A breast epithelial cells,
treatment with 10 ng/ml TNF-· increased cell proliferation
after 24 and 48 h. In rat breast epithelial cells TNF-· treat-
ment similarly increased proliferation (33,34). Our results
indicate that TNF-· treatment has a substantial and sustained
effect on promoting cell proliferation in MCF-10A cells.
PI3-kinase signalling is involved in breast cancer
development, its activation being linked to increased cell
growth (35). In MDA-MB-231 breast cancer cells, TNF-·
treatment did not change phosphorylation of AKT, while
in SK-BR-3 breast cancer cells, 10 ng/ml TNF-· treatment
increased phosphorylation of AKT. These are novel findings
as no other studies investigated the phosphorylation of AKT
after treatment with TNF-· in these cells. In one study, TNF-·
mediated activation of AKT has been linked to activation of
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Table I. Changes of cell population distribution across cell cycle stages after 24-h treatment with 10 ng/ml TNF-· in MDA-
MB-231 cells, SK-BR-3 cells and MCF-10A cells.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Sub-G1 (%) G1/G0 (%) S (%) G2 (%)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
MDA-MB-231
Control 16.98±1.07 55.12±0.40 7.23±0.65 12.88±0.43
10 ng/ml TNF-· for 24 h 21.64±1.44 51.64±1.14 5.43±0.58 12.38±0.42
UNIANOVA p<0.001 p=0.006 p<0.001 ns
SK-BR-3
Control 21.25±1.41 39.90±2.00 6.30±0.45 15.98±0.70
10 ng/ml TNF-· for 24 h 26.62±3.85 37.97±1.14 4.75±0.91 12.19±1.87
UNIANOVA ns ns p=0.011 p=0.011
MCF-10A
Control 23.17±1.28 65.23±1.50 1.27±0.09 6.60±0.41
10 ng/ml TNF-· for 24 h 27.50±2.33 58.61±2.54 1.54±0.19 7.60 0.76
UNIANOVA ns p=0.051 ns ns
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Values represent mean ± standard error of three independent experiments. Each experiment had two replicates, i.e. six data points for control
and treatment. ns, not significant.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
477-483.qxd  20/12/2010  12:33 ÌÌ  ™ÂÏ›‰·481
proliferation-stimulating transcription factor NF-κB in T47D
breast cancer cells (13). Thus, similarly activation of AKT
may be a pathway for TNF-· stimulated cell proliferation in
SK-BR-3 breast cancer cells. In MCF-10A breast epithelial
cells, 10 ng/ml TNF-· treatment did not change AKT-phos-
phorylation significantly. A non-significant increase of 77% in
AKT-phosphorylation after 20-min treatment was, however,
observed.
MAP-kinase signalling is involved in promoting cell
proliferation and apoptosis evasion in breast cancer cells
(36,37). TNF-· treatment significantly decreased phos-
phorylation of ERK1/2 in MDA-MB-231 breast cancer cells.
In the only comparable study, treatment of MDA-MB-231
breast cancer cells with 10 ng/ml TNF-· for 24 h induced
expression of MMP-9, which was reduced after inhibition of
MEK1/2 by 10 μM U0126, suggesting that TNF-· activates
ERK1/2 to exert this effect (38). This study, however, did
not examine ERK1/2-phosphorylation directly. Thus, there
is no confirmation to this finding. Additionally, ERK1/2-
phosphorylation slowly and non-significantly increased
between 5 and 20 min of treatment. Extension of treatment
time may be needed to determine, if this trend continues and
TNF-· treatment has a time-delay in inducing ERK1/2-
phosphorylation after increased treatment time. A reduction
in ERK1/2-phosphorylation is explained by TNF-·'s inter-
ference with the, by mutation of RAS and RAF, consti-
tutively activated MAP-kinase pathway. It also indicates,
however, a growth inhibitory effect of TNF-· on these cells,
which in the previous results had not been observed. In
SK-BR-3 breast cancer cells, 10 ng/ml TNF-· treatment
significantly increased phosphorylation of ERK1/2. This is
a novel finding and further supports the growth promoting
effect of TNF-· in this breast cancer cell line. With both PI3-
kinase and MAP-kinase pathway activated in response to
TNF-· treatment, it can not be ascertained which pathway
may promote the observed increase in cell proliferation. In
MCF-10A breast epithelial cells, 10 ng/ml TNF-· increased
phosphorylation of ERK1/2 significantly after between
10- and 20-min treatment. The highest increase was observed
after 10-min treatment. This indicates a sustained activation
of at least 10 min. The non-significant increase in AKT-
phosphorylation may suggest that the MAP-kinase may
be majorly responsible for mediating TNF-· induced cell
proliferation in this cell line.
In MDA-MB-231 breast cancer cells, 10 ng/ml TNF-·
treatment for 24 h significantly decreased the G1- and
S-phase population of the cell cycle profile. In addition, cells
with a DNA-content below that expected of cells in G1-phase
were measured. These cells were indicative of apoptotic
cells. In MDA-MB-231 breast cancer cells, this ‘subG1’
population increased significantly after TNF-· treatment.
This suggests that TNF-· may promote apoptosis in these
cells. This is a novel finding and in addition to the decrease
in ERK1/2 phosphorylation after TNF-· treatment suggests
a growth inhibiting and even apoptosis inducing effect of
TNF-· on MDA-MB-231 breast cancer cells. In SK-BR-3
breast cancer cells, 10 ng/ml TNF-· treatment significantly
decreased S-phase and G2-phase population after 24-h
treatment. There was, however, no indication of increased
apoptosis. A similar result was observed for T47D breast
cancer cells, where S-phase and G2-phase decreased after
treatment with 10 ng/ml TNF-· for 24 h (14). These authors
concluded that TNF-· induced cell cycle arrest at the G1/S
cell cycle checkpoint (14), which may similarly apply to
SK-BR-3 breast cancer cells. Cell cycle arrest is typically
associated with growth inhibition, thus, the cell cycle results
oppose the previous findings, all of which could be interpreted
as TNF-· promoting cell growth in SK-BR-3 breast cancer
cells. There is no conclusive explanation for this observation.
One may be confronted with a similar situation as observed
for different subtypes of the MCF-7 breast cancer cell line,
which showed opposing effects to TNF-· treatment (17).
In MCF-10A breast epithelial cells, 10 ng/ml TNF-· did
not change the distribution of the cell population across cell
cycle phases. G1-phase population decreased non-signi-
ficantly after TNF-· treatment (p=0.051). The probability
value is just above the cut-off point. A decrease in G1-
phase population could be interpreted as an increase in cell
cycle progression, thus complementing findings from the
cell proliferation results and cell signalling pathways. This
suggests that all experiments point to an increase in cell
growth in MCF-10A cells, following TNF-· treatment.
In conclusion, TNF-· affects the metabolism of breast
cancer cells and breast epithelial cells. The effect on breast
cancer cells is, however, not as comprehensive as the effect
on breast epithelial cells. In MDA-MB-231 breast cancer
cells the results generally suggest no effect on cell growth,
with some indications of growth inhibition and even
increased apoptosis after TNF-· treatment. Conversely,
results for SK-BR-3 cells generally indicate a growth
promoting effect of TNF-·, while the cell cycle results are
contradicting these findings. TNF-· exerts different and even
opposing effects between just two breast cancer cell lines,
suggesting there is no general mode of action of TNF-· on
breast cancer cells, but that different cells, and thus tumours,
may react differently to increased TNF-· concentrations. If
one assumes cell mosaicism in tumours, one may also specu-
late that cells of the same tumour could react differently to
TNF-·. As the majority of our results indicate growth
promotion in SK-BR-3 breast cancer cells, TNF-· can not
be excluded as a potential mediator in the link between
obesity and breast cancer progression. In MCF-10A breast
epithelial cells, TNF-· increases cell proliferation, with no
indication of cell cycle arrest or onset of apoptosis. This
significant finding introduces a potential and novel way of
impact of TNF-· on breast cancer aetiology and may provide
a new understanding in the link between obesity and increased
risk of breast cancer development.
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